| Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report P Horby, WS Lim, J Emberson, M Mafham, J Bell, L Linsell, N Staplin, ... MedRxiv, 2020.06. 22.20137273, 2020 | 11816* | 2020 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2042* | 2021 |
| Effect of hydroxychloroquine in hospitalized patients with Covid-19 RECOVERY Collaborative Group New England Journal of Medicine 383 (21), 2030-2040, 2020 | 1477 | 2020 |
| Empagliflozin in patients with chronic kidney disease EMPA-Kidney Collaborative Group New England Journal of Medicine 388 (2), 117-127, 2023 | 989 | 2023 |
| Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial PW Horby, M Mafham, JL Bell, L Linsell, N Staplin, J Emberson, ... The Lancet 396 (10259), 1345-1352, 2020 | 798 | 2020 |
| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... Jama 326 (6), 499-518, 2021 | 483 | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 448* | 2021 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial PW Horby, G Pessoa-Amorim, L Peto, CE Brightling, R Sarkar, K Thomas, ... Medrxiv, 2021 | 303 | 2021 |
| The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study WG Herrington, D Preiss, R Haynes, M von Eynatten, N Staplin, ... Clinical kidney journal 11 (6), 749-761, 2018 | 250 | 2018 |
| Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials C Baigent, JR Emberson, R Haynes, WG Herrington, P Judge, ... The Lancet 400 (10365), 1788-1801, 2022 | 249 | 2022 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 236 | 2022 |
| Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomized double-blind trial R Haynes, PK Judge, N Staplin, WG Herrington, BC Storey, A Bethel, ... Circulation 138 (15), 1505-1514, 2018 | 213 | 2018 |
| Dexamethasone in hospitalized patients with Covid-19-preliminary report L Chappell, P Horby, WS Lim, JR Emberson, M Mafham, JL Bell, L Linsell, ... The New England journal of medicine, 2020 | 142 | 2020 |
| The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review RL Morton, I Schlackow, B Mihaylova, ND Staplin, A Gray, A Cass Nephrology Dialysis Transplantation 31 (1), 46-56, 2016 | 124 | 2016 |
| Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies G Wong, N Staplin, J Emberson, C Baigent, R Turner, J Chalmers, ... BMc cancer 16, 1-11, 2016 | 107 | 2016 |
| Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, L Estcourt, L Peto, ... MedRxiv, 2021.03. 09.21252736, 2021 | 98 | 2021 |
| Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial Nephrology Dialysis Transplantation 37 (7), 1317-1329, 2022 | 91 | 2022 |
| Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP) R Haynes, N Staplin, J Emberson, WG Herrington, C Tomson, L Agodoa, ... American journal of kidney diseases 64 (1), 40-48, 2014 | 90 | 2014 |
| Smoking and adverse outcomes in patients with CKD: The Study of Heart and Renal Protection (SHARP) N Staplin, R Haynes, WG Herrington, C Reith, A Cass, B Fellström, ... American Journal of Kidney Diseases 68 (3), 371-380, 2016 | 88 | 2016 |
| Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients N Staplin, A de la Sierra, LM Ruilope, JR Emberson, E Vinyoles, ... The Lancet 401 (10393), 2041-2050, 2023 | 87 | 2023 |
